Featured

Lonza, a major CDMO, is to invest $518 million in a new, massive fill-finish manufacturing facility in Stein, Switzerland. According...

According to the third Real-World Evidence (RWE) benchmarking survey published in June 2022 by Deloitte, there is a segmentation of...

The oral, once-daily Zejula (niraparib) tablet, a first-line and recurrent upkeep care for women with advanced epithelial high-grade ovarian, fallopian...

Recent market analysis predicts that the international market for biopharmaceutical bioseparation systems, which is expected to be worth $13 billion...

The most prevalent kind of the disease, non-small cell lung cancer, has seen steady advancements in immunotherapies called checkpoint inhibitors...

As many Americans face difficult financial decisions thanks to inflation, a new study verifies what many have feared for years:...

It was a small study, with only 18 rectal cancer sufferers taking the same medicine. However, the outcomes were astounding....

The findings of a phase 1 trial examining a medication mixture targeting multiple mutant variants of cancer's 'death star' protein...

The Indian Council of Medical Research, the country's apex agency for biomedical research, has issued guidelines for the use of...